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Introduction: Successful treatment for HIV infection requires sus-
tained viral suppression (SVS). Patients with undetectable HIV-RNA
levels have a significantly lower risk of clinical disease progression. And
at community level viral suppression is important to reduce HIV
transmission and the emergence of resistant strains. The study aimed
to analyze the frequency and duration of viral suppression (VS) in the
first cohort of people living with HIV/AIDS (PLWHA) under treatment.
Methods: We retrospectively evaluated data from all PLWHA unin-
sured adults who initiated HAART through the National Program
during 20042006 and followed-up until 2012. Patients with com-
plete records in the National Laboratory Reporting System Data Base
were included. The duration of VS was analyzed using survival analysis
(Kaplan-Meier) in PLWHA who achieved viral suppression. Survival
time was measured between the first control with viral load 5400
copies/ml until the presence of first interruption or failure of viral sup-
pression (FSV) with viral load400 copies/ml. Persons lost to follow
up and those without FSV were censored. R Software 3.0.3.was used.
Results: During the study period a total of 6289 PLWHA had access to
health care settings for initial evaluation and only 5142 received
HAART. Of these, 4530(88%) achieved VS for variable time (respon-
ders) and 612 never presented VS (non-responders). Cumulative
survival rate was analyzed in responders: 91.1% maintained VS up to
one year, 84.6% up to two years, 80.2% to three years, 77.1% to four
years, 74.1% to five years and 70.1% to six years. According to
survival analysis, Kaplan-Meier curves presented lower duration of
VS in young adult patients, females, persons in prisons and those
who did not increase their CD4 above baseline. No differences were
observed with baseline CD4 and viral load (pB0.05).
Conclusions: This findings suggest that SVS as a programme indicator
is feasible and useful for monitoring health care settings and ranking
them like a control quality measure. SVS could also be included as
another parameter in cascade of treatment measures.
http://dx.doi.org/10.7448/IAS.18.5.20408
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Abstract WEAD0101Figure 1. Kaplan-Meier plots over the first 18-months in a Community-based Adherance Club: (a) LTFU by gender,
(b) LFTU by age, (c) Viral rebound by gender, (d) Viral rebound by age.
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Introduction: In a Universal Test and Treat (UTT) strategy, entry into
care soon after HIV diagnosis is crucial to achieve optimal popula-
tion-antiretroviral treatment (ART) coverage. We evaluated the rate
of, and factors associated with, entry into care following home-based
HIV testing in a cluster-randomized trial of the effect of immediate
ART on HIV incidence in rural KwaZulu-Natal, South Africa.
Methods: From March 2012 to May 2014, individuals ]16 years in
ten (25) clusters were offered home-based HIV testing; those
ascertained HIV-positive were referred to TasP trial clinics and were
offered universal and immediate ART (intervention clusters) or
according to national guidelines (control clusters). Entry into care
was defined as attending a TasP clinic within three months of referral
among adults not actively in HIV care (no visit to local HIV
programme within past 13 months). Associated factors were
identified separately by sex, using multivariable logistic regression.
Results: Overall, 1205 adults (72.6% women) not actively in HIV care
were referred to a TasP clinic. Of these, 405 (33.6%) attended a TasP
clinic within three months (no difference between trial arms): 32.5%
of women, 36.7% of men. Participants who ever visited the local HIV
programme (n360) were more likely to enter into care than those
who didn’t (women: adjusted odd-ratio (aOR) 1.76, 95% Confidence
Interval (1.262.45); men: 2.07 (1.183.64)). In women (n875),
those less likely to attend a TasP clinic within three months had
completed some secondary school (0.51 (0.330.79)) or at least
secondary school (0.47 (0.290.76)) versus below primary school;
were living 12 km from a TasP clinic (0.43 (0.300.62)) or 25 km
(0.40 (0.270.61)) versus B1 km; didn’t know anyone HIV within
their family (0.60 (0.430.81)) and didn’t agree that it is good to
initiate ART as soon as possible if infected (0.47 (0.260.85)); among
men (n330), none of the factors examined was significantly
associated with entry into care.
Conclusions: Only one-third of HIV-positive adults referred after
home-based HIV testing entered into care within three months in
this rural South African community with a 30% HIV prevalence.
Innovative interventions should be considered to ensure the success
of a UTT strategy.
http://dx.doi.org/10.7448/IAS.18.5.20409
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Introduction: Retention, combination antiretroviral therapy (cART)
use and viral suppression are key stages in the HIV Care Continuum
associated with delayed disease progression and reduced transmis-
sion. We assessed trends in these indicators within the large and
diverse CCASAnet cohort over a decade.
Methods: Adults from CCASAnet clinical cohorts in Argentina, Brazil,
Chile, Haiti, Honduras, Mexico and Peru contributed data from first
visit between 2003 and 2012 until final visit, death, or the end of
2012. Retention was ]2 HIV care visits in a year, 90 days apart.
cART use was prescription of a regimen of ]3 active antiretroviral
agents in a year. Viral suppression was HIV-1 RNAB200 copies/mL
at last measurement in the year. cART use and viral suppression
denominators were subjects with ]1 visit in the year. Multivariable
modified Poisson regression models were used to assess temporal
trends and predict percentages meeting each indicator in each year,
adjusting for age, sex, HIV transmission mode, cohort, calendar year
and total time in care.
Results: Among 18,799 individuals contributing to retention ana-
lyses, 14,380 to cART use analyses and 13,330 to viral suppression
Abstract WEAD0104Table 1. Person-years contributed and characteristics
Characteristic Not Retained
a
Retained
a
p* Not on cART
b
On cART
b
p*
Not virally
suppressed
c
Virally
suppressed
c
p*
Total 22,386 67,171 B0.01 11,565 57,312 B0.01 19,369 41,271 B0.01
Age (years) 33.9 (28.2, 40.6) 36.4 (30.0, 43.9) B0.01 32.5 (27.1, 39.3) 35.5 (29.6, 42.4) B0.01 33.5 (27.7, 40.4) 36.0 (30.1, 42.9) B0.01
Male sex 14,238 (25.1) 42,487 (74.9) 0.35 8119 (16.5) 40,982 (83.5) B0.01 13,493 (31.0) 29,981 (69.0) B0.01
Female sex 8148 (24.8) 24,684 (75.2) 3446 (17.4) 16,330 (82.6) 5876 (34.2) 11,290 (65.8)
MSM HIV risk 7050 (27.6) 18,503 (72.4) B0.01 5079 (18.6) 22,225 (81.4) B0.01 7537 (31.4) 16,489 (68.6) B0.01
IDU HIV risk 820 (52.7) 735 (47.3) 203 (15.1) 1141 (84.9) 349 (29.3) 842 (70.7)
Hetero HIV risk 8443 (29.2) 20,495 (70.8) 4800 (16.1) 24,945 (83.9) 8921 (34.4) 17,044 (65.6)
Other/unk.
HIV risk
6073 (18.1) 27,438 (81.9) 1483 (14.2) 9001 (85.9) 2562 (27.1) 6896 (72.9)
Individual years
in care
7 (4, 9) 7 (4, 9) B0.01 6 (3, 8) 8 (5, 10) B0.01 6 (4, 9) 8 (5, 10) B0.01
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